NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Other Events

ME Staff 8-k
-
0

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Other Events
Item 8.01  Other Information.

On April 17, 2017, Nabriva Therapeutics AG (the “Company”) issued a press release announcing that its supervisory board and management board approved the relocation of the holding company of the Company and its subsidiaries from Austria to Ireland (the “Redomiciliation Transaction”). The Redomiciliation Transaction is to be effected by the exchange of American depositary shares of the Company and common shares of the Company for shares of Nabriva Therapeutics Plc, a newly-formed Irish public limited company.

Item 9.01  Financial Statements and Exhibits.

(d)                                 Exhibits

See Exhibit Index attached hereto.


About NABRIVA THERAPEUTICS AG (NASDAQ:NBRV)

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Recent Trading Information

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) closed its last trading session down -0.25 at 11.16 with 5,271 shares trading hands.